Reportstack has announced a new market research report on the Global Osteoarthritis Market 2015-2019. The presence of various large and small pharmaceutical companies increases the competition in the market. Various vendors are extensively forming strategic alliances to increase their market share. For instance, in 2013, Merck Serono and Biopharm collaborated to research the molecular engineering of a biologic compound for the treatment of osteoarthritis. The Global Osteoarthritis market is expected to grow at a CAGR of 8.55 percent during the forecast period of 2014-2019.
“Various companies are conducting clinical trials of a new class of pain medications called anti-NGFs. These are biologic drugs that block NGF, a protein associated with pain,”.
To access full report with TOC, please visit Global Osteoarthritis (OA) Market 2015-2019.
“Moreover, the efficacy of selective PDE2 inhibitors is being evaluated in rat models to be used for relieving pain caused by osteoarthritis in humans.”
To define the market conditions in the next 3-4 years, the analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
Reportstack is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack members with cutting edge research products to facilitate strategic business decisions.
Manager - Marketing
Reportstack Market Research